Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00160173 · ClinicalTrials.gov registry record · Phase 4

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Phase 4 study of Postmenopausal Symptoms, sponsored by ASCEND Therapeutics.

Completed
Registry status
Phase 4
Development phase
221
Enrollment target
20
Study locations

NCT00160173 is a Phase 4 study of Postmenopausal Symptoms that has completed, run by ASCEND Therapeutics. The registered enrollment target is 221 participants, above the 66-participant average among 7 other Postmenopausal Symptoms trials with a reported enrollment target (235% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00160173, a Phase 4 study of Postmenopausal Symptoms, has completed, sponsored by ASCEND Therapeutics.

COMPLETED
Registry status
Phase 4
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Estrogel

Study Locations (20)

California

  • Site 104 - Carmichael
  • Site 42 - Encinitas
  • Site 21 - San Diego
  • Site 37 - San Diego
  • Site 78 - San Diego
  • Site 82 - San Diego

Connecticut

  • Site 69 - Avon
  • Site 58 - Bridgeport
  • Site 3 - Groton
  • Site 72 - Hartford
  • Site 54 - New Britain
  • Site 79 - Southport

Alabama

  • Site 112 - Birmingham
  • Site 74 - Mobile
  • Site 20 - Montgomery

Arkansas

  • Site 5 - Jonesboro
  • Site 88 - Little Rock
  • Site 95 - Little Rock

Arizona

  • Site 34 - Tucson
  • Site 68 - Tucson

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2004-12-02
Est. Completion 2005-09-06
Phase Phase 4

Sponsor

ASCEND Therapeutics

2 total trials

What the Registry Record Tells You About NCT00160173

The ClinicalTrials.gov registry entry for NCT00160173 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 66-participant average among 7 other Postmenopausal Symptoms trials with a reported enrollment target (235% higher). The listed sponsor is ASCEND Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postmenopausal Symptoms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00160173 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Alabama.

Frequently Asked Questions

What is clinical trial NCT00160173 about?

NCT00160173 is a clinical study titled "Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy". This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

What is the current status of trial NCT00160173?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 221 participants. The study started on 2004-12-02. Estimated completion is 2005-09-06.

What conditions does trial NCT00160173 study?

This clinical trial studies the following conditions: Postmenopausal Symptoms.

What interventions are being tested in trial NCT00160173?

The interventions under investigation include: Placebo (OTHER), Estrogel (DRUG).

Who is sponsoring clinical trial NCT00160173?

This trial is sponsored by ASCEND Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00160173 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postmenopausal Symptoms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.